Farmas USA

MSTX
Ana autoflagelate , te avisé para iniciar posición en corto cuando estaba en 0.65 y el RSI en 96 y despreciaste la oportunidad de hacerte un +50 %

viernes de apocalipsis, lunes de resurrección, martes de mazazo al resucitado y al hoyo con él, miércoles...todos haciendo cola en la consulta del psiquiatra.

Así es la semana de brujas! Entretenida ;)

MSTX

Lo hubiera cerrado el mismo día :)

#NVAX

http://www.bolsamania.com/noticias/politica/la-enfermedad-de-clinton-beneficia-a-las-farmaceuticas--1708202.html

GSK's Vaccines Outperform Other Groups, Achieving 11% Growth in Q2 

http://www.fiercepharma.com/vaccines/gsk-s-vaccines-outperform-other-groups-achieving-11-growth-q2 

THLD

Aguanta en el Nasdaq. Por eso subía.

As previously reported, on July 20, 2016, the staff of The NASDAQ Stock Market LLC (“Nasdaq”) granted Threshold Pharmaceuticals, Inc.’s (the “Company” ’s) request for an extension to comply with the $1.00 per share minimum bid price requirement for continued listing on the NASDAQ Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) as originally notified by the Staff on January 21, 2016. On September 13, 2016, the Company received written notice from the Staff that as a result of the closing bid price of the Company’s common stock having been at $1.00 per share or greater for the last 10 consecutive business days, from August 29 to September 12, 2016, the Staff has determined that the Company has regained compliance with the Bid Price Rule and this matter is now closed

http://investor.thresholdpharm.com/secfiling.cfm?filingid=1144204-16-123752&CIK=1183765

Hala, ya puede volver a bajar ja ja

THLD

XOMA

"As previously reported, on March 15, 2016 XOMA Corporation (“XOMA”) was notified by The NASDAQ Stock Market LLC (“NASDAQ”) that XOMA was out of compliance with NASDAQ Listing Rule 5450(a)(1), requiring maintenance of a minimum bid erice of $1.00 per share (“Minimum Bid Price Requirement”). At that time, NASDAQ advised that if XOMA failed to achieve compliance with the Minimum Bid Price Requirement in the period expiring on September 12, 2016, NASDAQ would notify XOMA that its securities would be subject to delisting (“Delisting Notice”).
Since in order to achieve compliance with the Minimum Bid Price Requirement, the closing bid price of XOMA’s common stock has to be at or above $1.00 for a minimum of 10 consecutive business days, XOMA will not achieve compliance with the Minimum Bid Price Requirement prior to September 12, 2016, and therefore expects that on or about September 13, 2016 it will receive a Delisting Notice from NASDAQ.
XOMA intends to exercise its right to appeal any Delisting Notice, which would suspend the delisting of XOMA’s common stock pending a final decision on the appeal. At or before a hearing on the appeal, XOMA will present a plan to effect a reverse split of its issued and outstanding shares of common stock as a means to regain compliance with the Minimum Bid Price Requirement, and continue the listing of XOMA common stock on The NASDAQ Global Market.
In furtherance of this plan, on September 2, 2016, XOMA filed a preliminary proxy statement on Schedule 14A for a planned special meeting of stockholders for the purpose of seeking stockholder approval of such reverse split. If stockholders approve and XOMA completes a reverse split as outlined in the proxy statement, XOMA expects the resultant market price of its shares would meet the Minimum Bid Price Requirement. While XOMA believes that its plan will be successful, there can be no guarantee."